Purpose: To assess caregivers' characteristics and influence of the presence or absence of the caregiver on clinical outcomes of older (≥70 years) metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone (ABI) or enzalutamide (ENZ). Methods: Patients from the Meet-URO 5 ADHERE study were assessed with a 5-item caregiver evaluation questionnaire focusing on the presence, age, degree of kinship, working status and qualification of the caregiver. We investigated the association between the presence of a caregiver and the clinical characteristics and outcomes of enrolled patients. Results: No differences were found in the main clinical characteristics between patients with or without a caregiver, except for a lower median G8 score (p = 0.0453) in the caregiver group. A longer radiographic PFS (rPFS) was observed in the group without a caregiver, with a trend towards more prolonged overall survival (OS) in the same group. Conclusion: Our work suggests a detrimental effect of caregivers in managing older mCRPC patients treated with ABI or ENZ, especially those identified as frail by the geriatric G8 screening score. Further work is needed to identify and address patients' vulnerability areas, which could have a detrimental effect on prognosis.

The role of the caregiver in older patients with advanced prostate cancer: results from the ADHERE Prospective Study of the Meet-URO network / Giunta, Emilio Francesco; De Padova, Silvia; Anpalakhan, Shobana; De Giorgi, Ugo; Maruzzo, Marco; Rebuzzi, Sara Elena; Cinausero, Marika; Fratino, Lucia; Lipari, Helga; Gamba, Teresa; Bimbatti, Davide; Dri, Arianna; Ermacora, Paola; Vignani, Francesca; Basso, Umberto; Buti, Sebastiano; Gandini, Annalice; Cremante, Malvina; Fornarini, Giuseppe; Rescigno, Pasquale; Banna, Giuseppe Luigi. - In: SUPPORTIVE CARE IN CANCER. - ISSN 0941-4355. - 31:7(2023), p. 425. [10.1007/s00520-023-07867-4]

The role of the caregiver in older patients with advanced prostate cancer: results from the ADHERE Prospective Study of the Meet-URO network

Buti, Sebastiano
Supervision
;
2023-01-01

Abstract

Purpose: To assess caregivers' characteristics and influence of the presence or absence of the caregiver on clinical outcomes of older (≥70 years) metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone (ABI) or enzalutamide (ENZ). Methods: Patients from the Meet-URO 5 ADHERE study were assessed with a 5-item caregiver evaluation questionnaire focusing on the presence, age, degree of kinship, working status and qualification of the caregiver. We investigated the association between the presence of a caregiver and the clinical characteristics and outcomes of enrolled patients. Results: No differences were found in the main clinical characteristics between patients with or without a caregiver, except for a lower median G8 score (p = 0.0453) in the caregiver group. A longer radiographic PFS (rPFS) was observed in the group without a caregiver, with a trend towards more prolonged overall survival (OS) in the same group. Conclusion: Our work suggests a detrimental effect of caregivers in managing older mCRPC patients treated with ABI or ENZ, especially those identified as frail by the geriatric G8 screening score. Further work is needed to identify and address patients' vulnerability areas, which could have a detrimental effect on prognosis.
2023
The role of the caregiver in older patients with advanced prostate cancer: results from the ADHERE Prospective Study of the Meet-URO network / Giunta, Emilio Francesco; De Padova, Silvia; Anpalakhan, Shobana; De Giorgi, Ugo; Maruzzo, Marco; Rebuzzi, Sara Elena; Cinausero, Marika; Fratino, Lucia; Lipari, Helga; Gamba, Teresa; Bimbatti, Davide; Dri, Arianna; Ermacora, Paola; Vignani, Francesca; Basso, Umberto; Buti, Sebastiano; Gandini, Annalice; Cremante, Malvina; Fornarini, Giuseppe; Rescigno, Pasquale; Banna, Giuseppe Luigi. - In: SUPPORTIVE CARE IN CANCER. - ISSN 0941-4355. - 31:7(2023), p. 425. [10.1007/s00520-023-07867-4]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2949532
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact